

CLAIMS

1. A method of promoting oligodendrocyte survival in a human suffering or at risk of developing stroke or another neurological disease which comprises administering to said human a therapeutically effective amount of an anti-MAG antibody or a functional fragment thereof.
2. Use of an anti-MAG antibody or functional fragment thereof for the manufacture of a medicament for the promotion of oligodendrocyte survival in a human suffering from or at risk of developing stroke or another neurological disease.
3. A method according to claim 1 or use according to claim 2 wherein the anti-MAG antibody is an altered antibody.
4. A method according to claim 1 or a use according to claim 2 wherein the anti-MAG antibody is a chimeric antibody.
5. A method according to claim 1 or a use according to claim 2 wherein the anti-MAG antibody is a humanised antibody.
6. Use or a method according to claims 3 - 5 wherein the altered antibody or functional fragment thereof binds to MAG and comprises one or more of the following CDR's.

Light chain CDRs

| CDR | According to Kabat |
|------------|---------------------------|
| L1 | KSSHSVLYSSNQKNYLA |
| L2 | WASTRES |
| L3 | HQYLSSLT |

Heavy chain CDRs

| CDR | According to Kabat |
|------------|---------------------------|
| H1 | NYGMN |
| H2 | WINTYTGEPTYADDFTG |
| H3 | NPINYYGINYEGYVMDY |

7. Use or a method according to claim 6 wherein the altered antibody or functional fragment thereof comprises a heavy chain variable domain which comprises one or more CDR's selected from CDRH1, CDRH2 and CDRH3 and for a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3 .

8. Use or a method according to claim 7 wherein the altered anti-MAG antibody or functional fragment thereof comprises:

a heavy chain variable domain (V_H) which comprises in sequence hypervariable regions CDRH1, CDRH2 and CDRH3

and /or

a light chain variable domain (V_L) which comprises in sequence hypervariable regions CDRL1, CDRL2 and CDRL3.

9. Use or a method according to claim 8 wherein the altered MAG antibody or functional fragment thereof comprises a heavy chain of Sequence ID No. 7 or 9 and/or a light chain Sequence ID No. 8.

10. Use or a method according to claim 8 wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region selected from Sequence ID No. 10, 11, 12 or 13 and/or a light chain variable region selected from Sequence ID No. 14, 15, 16 or 17.

11. Use or a method according to claim 10 wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region Sequence ID No. 10 and a light chain variable region selected from Sequence ID No. 14, 15, 16 or 17.

12. Use or a method according to claim 10 wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region Sequence ID No. 11 and a light chain variable region selected from Sequence ID No. 14, 15, 16 or 17.

13. Use or a method according to claim 10 wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region Sequence ID No. 12 and a light chain variable region selected from Sequence ID No. 14, 15, 16 or 17.

14. Use or a method according to claims 10 – 13 wherein the antibody is a humanised antibody and comprises a heavy chain variable fragment comprising SEQ ID No 10, 11 or 12 and a constant part or fragment thereof of a human chain and a light chain variable fragment comprising SEQ ID No 14, 15, 16 or 17 and a constant part or fragment thereof of a human light chain.

15. Use or a method according to claim 14 wherein the humanised antibody is class 1gG.

16. Use or a method according to claim 15 wherein the humanised antibody is 1gG1.

17. Use or a method according to claims 16 wherein the heavy chain is:

MGWSCIIILFLVATATGVHSQVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWRQAPG
QGLEWMGWINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPINYYG
INIEGYVMDYWGGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW
NSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD
KTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSK
LTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK (Seq ID No 18)

18. Use or a method according to claim 16 wherein the antibody light chain is:

MGWSCIIILFLVATATGVHSDIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNQKNYLAWYQQ
KPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYLSSLTFGQGT
KLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPPREAKVQWKVDNALQSGNSQESVTE
QDSKDSSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Seq ID No 19)

- 19 Use a method according to any preceding claim wherein the antibody is an antibody which binds to the same epitope as the antibody having the CDR's of claim 6.